Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
By Natalie Grover LONDON (Reuters) -Shares in Biogen and Eisai soared on Wednesday reflecting the surprise trial success of their experimental Alzheim.
Shares in Biogen and Eisai soared on Wednesday reflecting the surprise trial success of their experimental Alzheimer s drug, which also lifted the stocks of rival drugmakers Roche and Eli Lilly.
Biogen shares soar on landmark Alzheimer s data, lift rivals malaymail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaymail.com Daily Mail and Mail on Sunday newspapers.